Clinical data
AHFS/Drugs.com International Drug Names
ATC code A10BF03 (WHO)
CAS Number 83480-29-9 YesY
PubChem (CID) 444020
DrugBank DB04878 YesY
ChemSpider 392046 YesY
UNII S77P977AG8 YesY
KEGG D01665 YesY
Chemical and physical data
Formula C10H21NO7
Molar mass 267.28 g/mol
3D model (Jmol) Interactive image

Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[1]

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.


This article is issued from Wikipedia - version of the 6/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.